Medi Assist Q1FY26 profit up 22% as revenue jumps 24%

Key takeaway for investors

Medi Assist Healthcare Services Ltd reported higher profitability and revenue growth for the quarter ended June 30, 2026, alongside a ₹2 per share final dividend announcement. The company attributed the topline lift to higher volumes and consolidation of Paramount Health Services and Insurance TPA Private Limited after its acquisition. Statutory auditors issued an unmodified limited review report on the unaudited results. The auditors also flagged an ongoing Directorate of Enforcement (ED) probe at a subsidiary, while stating there was no material financial impact noted in the period under review. Separately, the company also communicated a board meeting date and an earnings call schedule linked to the June 2026 quarter results.

Q1 performance: consolidated profit and revenue rise

For the quarter ended June 30, 2026, Medi Assist reported consolidated net profit of ₹275.97 million, a 21.9% increase from ₹226.31 million in the same period a year earlier. Consolidated revenue from operations rose 24.1% year-on-year to ₹2,365.19 million from ₹1,905.58 million. The company linked the growth to higher volumes and the inclusion of Paramount Health Services and Insurance TPA Private Limited following its acquisition. Basic earnings per share (EPS) on a consolidated basis increased to ₹3.71 from ₹3.18. The reported numbers indicate a faster rise in revenue than profit in the quarter, even as profit growth remained above 20%.

Standalone numbers show sharper profit growth

On a standalone basis, Medi Assist reported net profit of ₹131.52 million, up 64.0% from ₹80.20 million in Q1FY25. Standalone revenue from operations increased to ₹589.84 million from ₹437.04 million. Standalone basic EPS rose to ₹1.76 from ₹1.14. The divergence between consolidated and standalone growth rates suggests the quarter also reflected group-level consolidation effects alongside stronger performance in the standalone business.

Dividend declared and record date announced

The Board of Directors approved a final dividend of ₹2 per equity share for the financial year 2025-26. The record date for determining eligible shareholders was fixed for September 11, 2026. Final dividends typically require shareholder approval in line with applicable procedures, and record dates are used to determine entitlement based on shareholding on that date. The disclosure places the dividend decision alongside the quarterly financial update, giving investors a clear timeline for eligibility.

Management reshuffle and governance note

The board also reshuffled top management, with Dr. Vikram Jit Singh Chhatwal stepping down as Whole-Time Director to focus on governance, as stated in the provided information. In a separate earnings call invite included in the same material, Dr. Vikram Chhatwal is listed among scheduled participants, described as Chairman and Whole-time Director, alongside CEO Satish Gidugu and CFO Sandeep Daga. The disclosures, as presented, therefore carry different role descriptions for the same individual. The company’s scheduled investor interaction indicates management will address the quarter’s performance and related updates.

Auditor review and the ED probe reference

Statutory auditors MSK A & Associates LLP issued an unmodified review report on the unaudited financial results. The auditors stated that the results were prepared in accordance with Ind AS 34 and Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The auditors also noted an ongoing ED probe, while confirming no material financial impact. In earlier consolidated reporting referenced in the material, a “search and seizure operation” by the Directorate of Enforcement was mentioned at a wholly owned subsidiary (MAITPA), with management believing there would be no adverse impact.

Board meeting, trading window closure, and earnings call schedule

Medi Assist communicated that its board meeting is scheduled for Saturday, August 8, 2026, to consider and approve unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. The company also scheduled an earnings call for Monday, August 10, 2026 at 8:30 am IST to discuss the same financial results. The trading window for designated persons was stated to have closed on July 1, 2026 and will remain closed until 48 hours after the declaration of the financial results. Investor queries were directed to investor.relations@mediassist.in.

Snapshot table: Q1 performance metrics

Market datapoints and externally shared estimates

The material cited the stock trading around ₹359 and also referenced a current market price (CMP) of ₹363 in another section. Market capitalisation was cited at about ₹2.9K crore, with another figure of ₹2,875 crore and a separate mention of ₹2,719 crore. The price-to-earnings (P/E) multiple was mentioned at 29.9 and also 30.4 across the excerpts.

The same material also included a Q1 FY27 estimate range, presented as an external preview, with revenue projected at ₹2,280-2,620 million and net profit (PAT) projected at ₹300-380 million, alongside a stated 12-month target price range of ₹430-478. These figures were explicitly labelled as estimates and sit alongside the company’s own timetable for board approval and an earnings call.

Timeline table: key dates investors can track

Why the update matters

Two elements stand out in the disclosures: first, the quarter’s reported revenue increase was linked to both business volumes and the integration of Paramount Health Services and Insurance TPA Private Limited after the acquisition. Second, the company’s governance and compliance narrative remains in focus due to the auditor’s reference to an ongoing ED probe, even as the auditor stated there was no material financial impact. For investors, the combination of reported profit growth, dividend declaration, and the scheduled August 2026 events creates a clear near-term calendar for monitoring results, management commentary, and any incremental disclosures.

Conclusion

Medi Assist’s quarter ended June 30, 2026 showed a 21.9% year-on-year rise in consolidated net profit to ₹275.97 million and a 24.1% rise in revenue to ₹2,365.19 million, with consolidation benefits from the Paramount acquisition cited as a driver. The company also announced a ₹2 final dividend with a September 11, 2026 record date, while auditors issued an unmodified review report and referenced an ED probe with no material financial impact noted. The next formal update is scheduled through the board meeting on August 8, 2026, followed by the management earnings call on August 10, 2026.